Arctigenin
Alternative Names: Arctium lappa extract; ARG; Burdock fruit extract; GBS-01Latest Information Update: 31 Oct 2021
At a glance
- Originator National Cancer Center (Tokyo)
- Developer Kracie Pharma; National Cancer Center (Tokyo); Toyama Medical and Pharmaceutical University
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 22 Mar 2019 No development reported - Phase-II for Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in Japan (PO)
- 03 Oct 2016 National Cancer Center Hospital East and Kracie Pharma completes a phase II trial in Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in Japan (UMIN000010111)